ImmunityBio, Inc.
US ˙ NasdaqGS ˙ US45256X1037

SecurityIBRX / ImmunityBio, Inc.
InstitutionPrivate Advisor Group, LLC
Latest Disclosed Ownership1,648,556 shares
Latest Disclosed Value $ 12,644,425
Private Advisor Group, LLC reports 923.48% increase in ownership of IBRX / ImmunityBio, Inc.

On April 24, 2026 - Private Advisor Group, LLC filed a 13F-HR form disclosing ownership of 1,648,556 shares of ImmunityBio, Inc. (US:IBRX) valued at $12,644,425 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 161,074 shares of ImmunityBio, Inc.. This represents a change in shares of 923.48% during the quarter. The current value of the position is $11,836,632 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F IMMUNITYBIO COM 45256X103 1,648,556 1,487,482 923.48 12,644 3,876.10 0.0593
2026-02-17 2025-12-31 13F IMMUNITYBIO COM 45256X103 161,074 148,222 1,153.30 319 925.81 0.0015
2025-11-13 2025-09-30 13F IMMUNITYBIO COM 45256X103 12,852 -203 -1.55 32 -8.82 0.0002
2025-08-11 2025-06-30 13F IMMUNITYBIO COM 45256X103 13,055 203 1.58 34 -10.53 0.0002
2025-05-05 2025-03-31 13F IMMUNITYBIO COM 45256X103 12,852 -598 -4.45 39 11.76 0.0002
2025-02-03 2024-12-31 13F IMMUNITYBIO COM 45256X103 13,450 -41,317 -75.44 34 -83.25 0.0002
2024-10-22 2024-09-30 13F IMMUNITYBIO COM 45256X103 54,767 -32,140 -36.98 204 -63.02 0.0013
2024-08-05 2024-06-30 13F IMMUNITYBIO COM 45256X103 86,907 76,407 727.69 549 880.36 0.0037
2024-04-30 2024-03-31 13F IMMUNITYBIO COM 45256X103 10,500 0 0.00 56 7.69 0.0004
2024-02-06 2023-12-31 13F IMMUNITYBIO COM 45256X103 10,500 10,500 53 0.0004
2020-10-30 2020-09-30 13F NANTKWEST COM 63016Q102 0 -500 -100.00 0 -100.00
2020-08-17 2020-06-30 13F NANTKWEST COM 63016Q102 500 500 6 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.